Attitudes toward genetic testing in patients with inflammatory bowel disease

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 4, 2007, Pages 321-327

  Lal, Simon ^a   Appelton, Jennifer ^a   Mascarenhas, Justine ^a   Stempak, Joanne M ^a   Esplen, Mary Jane ^a   Silverberg, Mark S ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Attitudes; Crohn's disease; Genetic testing; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADULT; ARTICLE; ATTITUDE TO GENETIC TESTING; CROHN DISEASE; ENTERITIS; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PATIENT ATTITUDE; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; ULCERATIVE COLITIS;

ADULT; ATTITUDE; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PREDICTIVE VALUE OF TESTS;

EID: 33947107047     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328013e9a8     Document Type: Article

References (22)

1. Ahmad T, Tamboli CP, Jewell D, Colombel JF. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 2004; 126:1533-1549.
2. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988; 29:990-996.
3. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
4. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606.
5. Ahmad T, Armuzzi A, Neville M, Bunce M, Ling KL, Welsh KI, et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens 2003; 62:527-535.
6. Satsangi J, Welsh KI, Bunce M, Julier C, Farrant JM, Bell JI, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996; 347:1212-1217.
7. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002; 122:854-866.
8. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122:867-874.
9. Arnott ID, Nimmo ER, Drummond HE, Fennell J, Smith BR, MacKinlay E, et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun 2004; 5:417-425.
10. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123:679-688.
11. Radlmayr M, Torok HP, Martin K, Folwaczny C. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology 2002; 122:2091-2092.
12. Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002; 123:106-111.
13. Esplen MJ, Madlensky L, Butler K, McKinnon W, Bapat B, Wong J, et al. Motivations and psychosocial impact of genetic testing for HNPCC. Am J Med Genet 2001; 103:9-15.
14. Chamaillard M, Iacob R, Desreumaux P, Colombel JF. Advances and perspectives in the genetics of inflammatory bowel diseases. Clin Gastroenterol Hepatol 2006; 4:143-151.
15. Esters N, Pierik M, van Steen K, Vermeire S, Claessens G, Joossens S, et al. Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99:299-305.
16. Rubin DT. To test or 'NOD-2' test: what are the questions? The balanced viewpoint. Inflamm Bowel Dis 2005; 11:510-512.
17. Silverberg MS. The time has come for NOD2/CARD15 testing for families with Crohn's disease: pro. Inflamm Bowel Dis 2005; 11:504-506.
18. Russel MG, Ryan BM, Dagnelie PC, de Rooij M, Sijbrandij J, Feleus A, et al. Insurance problems among inflammatory bowel disease patients: results of a Dutch population based study. Gut 2003; 52:358-362.
19. Calsbeek H, Rijken M, Dekker J, van Berge Henegouwen GP. Disease characteristics as determinants of the labour market position of adolescents and young adults with chronic digestive disorders. Eur J Gastroenterol Hepatol 2006; 18:203-209.
20. Adam S, Wiggins S, Whyte P, Bloch M, Shokeir MH, Soltan H, et al. Five year study of prenatal testing for Huntington's disease: demand, attitudes, and psychological assessment. J Med Genet 1993; 30:549-556.
21. Lerman C, Hughes C, Trock BJ, Myers RE, Main D, Bonney A, et al. Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 1999; 281:1618-1622.
22. Konda V, Huo D, Hermes G, Liu M, Patel R, Rubin DT. Do patients with inflammatory bowel disease want genetic testing? Inflamm Bowel Dis 2006; 12:497-502.